Eli Lilly CEO ‘definitely wants Mounjaro to be listed on the PBS’
News
Despite walking away from the deal earlier this year and price negotiations stalling, the drug’s…
Sound baths: What are they, how do they work, benefits, negatives, and everything to know, explained | The science (or lack thereof) behind them
A quick search for ‘south bath Sydney’ brings up dozens of pages plastered with photos of zen-looking women…
FDA Approves Drug for Narcolepsy – The Presidential Prayer Team
An official says this is the first drug that addresses the underlying biology of the disease. The Food…
‘A tax on being thin’: only high earners make overall savings on food bills from weight-loss drugs | Weight-loss drugs
The high cost of weight-loss medication is a “regressive tax on being thin” because the outlay outweighs any…
This Metal Pill Organizer Keeps Medication Safe and Secure
As an aging millennial, the number of pills I take every day seems to be slowly growing. So…
Kratom’s growing popularity raises questions over benefits and risks
COLORADO SPRINGS, Colo. (KKTV) – A plant native to Southeast Asia is gaining popularity in the U.S., including…
Homoeopaths Can’t Practice Other System Of Medicine: Homoeopathy Panel
New Delhi: The National Commission for Homoeopathy (NCH) has said that homoeopathic practitioners cannot practice any other system…
GLP-1 Bridge Program patient has difficulty getting medication
GLP-1 Bridge Program patient has difficulty getting medication GLP-1 Bridge Program Patient has difficulty getting medication Some Medicare…
Alzheimer’s: Common Blood Thinner May Slow Cognitive Decline
Share on PinterestNew research suggests that newer blood thinners may not only protect against strokes but also support…
EXCLUSIVE: Drug companies choosing not to sell life-saving and life-extending medicines in Canada
When Ruchi Ambike found out that Novartis got Health Canada approval for Vanrafia she was ecstatic. The drug…
The hidden risk of GLP-1 drugs | Fortune
There’s something the tens of millions of Americans who are currently on GLP-1 medications, or thinking of starting them, need to know. When patients rapidly…
Vimseltinib (romvimza) approved for use in adults to treat tenosynovial giant cell tumours
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (14 August 2026) approved vimseltinib (romvimza) to treat adult patients with tenosynovial…